二甲双胍联合艾塞那肽治疗2型糖尿病合并肥胖病患者的临床疗效

摘要

Objective To study the clinical efficacy of metformin combined with exenatide on patients with type 2 diabetes complicated with obesity.Methods Total of 66 patients with type 2 diabetes complicated with obesity in Wuhan Puren Hospital from Jan.2014 to Jan.2015 were included in the study,according to a random number table they were divided into an observation group and a control group , 33 cases in each group.The control group was treated with metformin(500 mg/time,3 times/day),the observation group was added exenatide (5 μg/time,1 time/day) for treatment on the basis of the control group.The clinical param-eters,blood pressure,blood sugar,blood lipid changes of the two groups before and after treatment were com-pared.Results After treatment,the hip circumference,waist circumference,body fat ratio,body mass index, fasting plasma glucose,postprandial 2 h plasma glucose,low-density lipoprotein,total cholesterol,triglycerides of the observation group were significantly lower than the control group[(93 ±5) cm vs (95 ±6) cm,(80 ± 4) cm vs (84 ±5) cm,(23 ±3)% vs (25 ±4) %,(23 ±2) kg/m2 vs (25 ±3) kg/m2,(8.3 ± 1.3) mmol/L vs (10.3 ±1.9) mmol/L,(9.0 ±2.3) mmol/L vs (11.5 ±2.9) mmol/L,(2.45 ± 0.24) mmol/L vs (3.02 ±0.37) mmol/L,(4.7 ±0.5) mmol/L vs (6.03 ±1.11) mmol/L,(2.4 ± 0.4) mmol/L vs (3.2 ±0.9) mmol/L],the high-density lipoprotein was higher than the control group [(1.62 ±0.42) mmol/L vs (1.23 ±0.21) mmol/L],the differences were statistically significant(P <0.05).Adverse reaction rates of the two groups were not significantly different(P >0.05).Conclusion Metformin combined with exenatide treatment of patients with type 2 diabetes complicated with obesity,can significantly lower blood sugar,blood lipid levels,with good safety and clinical efficacy.%目的：观察二甲双胍联合艾塞那肽治疗2型糖尿病合并肥胖病患者的临床疗效。方法选取2014年1月至2015年1月武汉市普仁医院收治的2型糖尿病合并肥胖患者66例，按照随机数字表法分为观察组和对照组，各33例。对照组采用二甲双胍进行治疗（500 mg／次，每日3次），观察组患者在此基础上给予艾塞那肽（5μg／次，1次／d ）进行治疗。比较两组患者治疗前后的临床指标、血压、血糖、血脂情况变化。结果治疗后，观察组患者的臀围、腰围、体内脂肪比、体质指数、空腹血糖、餐后2 h血糖、低密度脂蛋白胆固醇、总胆固醇、三酰甘油显著低于对照组[（93±5） cm比（95±6） cm，（80±4） cm比（84±5） cm，（23±3）％比（25±4）％，（23±2） kg／m2比（25±3） kg／m2，（8.3±1.3） mmol／L 比（10.3±1.9） mmol／L，（9.0±2.3） mmol／L 比（11.5±2.9） mmol／L，（2.45±0.24） mmol／L 比（3.02±0.37） mmol／L，（4.7±0.5） mmol／L 比（6.03±1.11） mmol／L，（2.4±0.4） mmol／L 比（3.2±0.9） mmol／L]，高密度脂蛋白胆固醇高于对照组[（1.62±0.42） mmol／L 比（1.23±0.21） mmol／L]，差异有统计学意义（P＜0.05）。两组患者的不良反应发生率差异无统计学意义（ P＞0.05）。结论二甲双胍联合艾塞那肽治疗2型糖尿病合并肥胖病患者，能明显降低患者的血糖、血脂水平，安全性高，临床疗效良好。